MCID: VSC007
MIFTS: 63

Vascular Disease

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Vascular Disease

MalaCards integrated aliases for Vascular Disease:

Name: Vascular Disease 12 15 17
Vascular Diseases 54 42 43 15 71
Spinal Cord Ischemia 43 17 71
Spinal Cord Vascular Diseases 43 71
Aneurysm 43 71
Vascular Tissue Disease 12
Vascular Anomaly 54

Classifications:



External Ids:

Disease Ontology 12 DOID:178
ICD9CM 34 442.9
SNOMED-CT 67 27550009 85659009
ICD10 32 I72.9
UMLS 71 C0002940 C0042373 C0752127 more

Summaries for Vascular Disease

MedlinePlus : 42 What are vascular diseases? Your vascular system is your body's network of blood vessels. It includes your Arteries, which carry oxygen-rich blood from your heart to your tissues and organs Veins, which carry the blood and waste products back to your heart Capillaries, which are tiny blood vessels that connect your small arteries to your small veins. The walls of the capillaries are thin and leaky, to allow for an exchange of materials between your tissues and blood. Vascular diseases are conditions which affect your vascular system. They are common and can be serious. Some types include Aneurysm - a bulge or "ballooning" in the wall of an artery Atherosclerosis - a disease in which plaque builds up inside your arteries. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Blood clots, including deep vein thrombosis and pulmonary embolism Coronary artery disease and carotid artery disease, diseases that involve the narrowing or blockage of an artery. The cause is usually a buildup of plaque. Raynaud's disease - a disorder that causes the blood vessels to narrow when you are cold or feeling stressed Stroke - a serious condition that happens when blood flow to your brain stops. Varicose veins - swollen, twisted veins that you can see just under the skin Vasculitis - inflammation of the blood vessels What causes vascular diseases? The causes of vascular diseases depend on the specific disease. These causes include Genetics Heart diseases such as high cholesterol and high blood pressure Infection Injury Medicines, including hormones Sometimes the cause is unknown. Who is at risk for vascular diseases? The risk factors for vascular diseases can vary, depending on the specific disease. But some of the more common risk factors include Age - your risk of some diseases goes up as you get older Conditions that can affect the heart and blood vessels, such as diabetes or high cholesterol Family history of vascular or heart diseases Infection or injury that damages your veins Lack of exercise Obesity Pregnancy Sitting or standing still for long periods of time Smoking What are the symptoms of vascular diseases? The symptoms for each disease are different. How are vascular diseases diagnosed? To make a diagnosis, your health care provider will do a physical exam and ask about your symptoms and medical history. You may have imaging tests and/or blood tests. How are vascular diseases treated? Which treatment you get depends on which vascular disease you have and how severe it is. Types of treatments for vascular diseases include Lifestyle changes, such as eating a heart-healthy diet and getting more exercise Medicines, such as blood pressure medicines, blood thinners, cholesterol medicines, and clot-dissolving drugs. In some cases, providers use a catheter to send medicine directly to a blood vessel. Non-surgical procedures, such as angioplasty, stenting, and vein ablation Surgery Can vascular diseases be prevented? There are steps you can take to help prevent vascular diseases: Make healthy lifestyle changes, such as eating a heart-healthy diet and getting more exercise Don't smoke. If you are already a smoker, talk to your health care provider for help in finding the best way for you to quit. Keep your blood pressure and cholesterol in check If you have diabetes, control your blood sugar Try not to sit or stand for up long periods of time. If you do need to sit all day, get up and move around every hour or so. If you traveling on a long trip, you can also wear compression stockings and regularly stretch your legs.

MalaCards based summary : Vascular Disease, also known as vascular diseases, is related to peripheral vascular disease and intracranial berry aneurysm, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Vascular Disease is MIR145 (MicroRNA 145), and among its related pathways/superpathways are Development VEGF signaling via VEGFR2 - generic cascades and Folate Metabolism. The drugs Ticlopidine and Ustekinumab have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and smooth muscle, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A cardiovascular system disease that primarily affects the blood vessels which includes the arteries, veins and capillaries that carry blood to and from the heart.

Wikipedia : 74 Vascular disease is a class of diseases of the blood vessels - the arteries and veins of the circulatory... more...

Related Diseases for Vascular Disease

Diseases in the Vascular Disease family:

Rare Vascular Disease

Diseases related to Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2504)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 35.9 VWF VEGFA VCAM1 SERPINE1 SELP SELE
2 intracranial berry aneurysm 35.4 SELE NOS3 EDN1 CRP APOE
3 hepatic vascular disease 35.0 VWF VEGFA SERPINE1 NOS3 MIR214 EDN1
4 retinal vascular disease 34.9 VEGFA VCAM1 NOS3 MTHFR MIR21 INS
5 buerger disease 34.3 SERPINE1 SELE NOS3 MTHFR
6 polycystic kidney disease 33.9 VEGFA NOS3 EDN1 ACE
7 arteriosclerosis 33.8 VCAM1 SERPINE1 SELP SELE PON1 NOS3
8 autosomal dominant polycystic kidney disease 33.7 VEGFA VCAM1 NOS3 INS EDN1 ACE
9 renal artery disease 33.7 NOS3 CRP ACE
10 cerebrovascular disease 33.6 VWF VCAM1 SERPINE1 SELP SELE PON1
11 thrombosis 33.6 VWF VCAM1 SERPINE1 SELP SELE NOS3
12 ischemia 33.6 VEGFA SELP PON1 NOS3 EDN1 ACE
13 vasculitis 33.5 VWF VCAM1 SELP SELE CRP
14 vein disease 33.5 VWF VEGFA SERPINE1 MTHFR INS EDN1
15 portal vein thrombosis 33.4 SERPINE1 SELP MTHFR CRP
16 carpal tunnel syndrome 33.2 VEGFA INS ACE
17 fabry disease 33.2 PON1 NOS3 CRP
18 chronic thromboembolic pulmonary hypertension 33.1 EDN1 CRP
19 intermittent claudication 33.1 VWF VEGFA SERPINE1 SELP CRP ACE
20 arteriosclerosis obliterans 33.0 VCAM1 SELP MIR21
21 atherosclerosis susceptibility 32.6 VWF VEGFA VCAM1 SERPINE1 SELP SELE
22 cholesterol embolism 32.5 CRP ACE
23 peripheral artery disease 32.5 VWF VEGFA VCAM1 SELP NOS3 EDN1
24 homocysteinemia 32.4 VWF VCAM1 SERPINE1 PON1 NOS3 MTHFR
25 raynaud disease 32.4 EDN1 CRP ACE
26 arteries, anomalies of 32.4 VWF VEGFA VCAM1 SERPINE1 SELP SELE
27 pulmonary hypertension 32.3 VWF VEGFA SERPINE1 SELP NOS3 MIR21
28 kidney disease 32.3 VWF VEGFA VCAM1 SERPINE1 PON1 NOS3
29 carotid stenosis 32.3 VEGFA VCAM1 SELP SELE NOS3 MTHFR
30 lipid metabolism disorder 32.3 SERPINE1 SELE PON1 INS CRP APOE
31 coronary heart disease 1 32.2 VWF VCAM1 SERPINE1 SELP SELE PON1
32 aortic valve disease 1 32.2 VWF NOS3 MIR21 EDN1 ACE
33 chronic kidney disease 32.2 VEGFA SERPINE1 PON1 NOS3 MTHFR INS
34 hypercholesterolemia, familial, 1 32.2 NOS3 INS CRP APOE ACE
35 limb ischemia 32.2 VWF VEGFA SERPINE1 SELE NOS3 EDN1
36 pre-eclampsia 32.2 VWF VEGFA VCAM1 SERPINE1 SELP SELE
37 diabetes mellitus 32.1 VWF VEGFA VCAM1 SERPINE1 SELP SELE
38 pericardial effusion 32.1 VEGFA CRP ACE
39 vascular dementia 32.1 VEGFA PON1 MTHFR CRP APOE ACE
40 stroke, ischemic 32.0 VWF SERPINE1 SELP PON1 NOS3 MTHFR
41 aortic aneurysm, familial abdominal, 1 32.0 CRP APOE ACE
42 congestive heart failure 32.0 VEGFA NOS3 INS EDN1 CRP ACE
43 lung disease 32.0 VEGFA INS EDN1 CRP ACE
44 retinal vein occlusion 32.0 VEGFA SERPINE1 MTHFR EDN1 ACE
45 carotid artery disease 32.0 SELP SELE PON1 CRP APOE ACE
46 hyperglycemia 32.0 VCAM1 SERPINE1 SELE NOS3 INS
47 microvascular complications of diabetes 5 32.0 VEGFA VCAM1 SERPINE1 PON1 NOS3 MIR21
48 aortic aneurysm 32.0 MIR145 CRP APOE ACE
49 pulmonary embolism 31.9 VWF SERPINE1 MTHFR CRP ACE
50 impotence 31.9 NOS3 INS EDN1 ACE

Graphical network of the top 20 diseases related to Vascular Disease:



Diseases related to Vascular Disease

Symptoms & Phenotypes for Vascular Disease

UMLS symptoms related to Vascular Disease:


angina pectoris, edema, chest pain, flushing, leg cramps, warm skin, vein pain

MGI Mouse Phenotypes related to Vascular Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.13 ACE APOE CRP EDN1 INS NOS3
2 homeostasis/metabolism MP:0005376 10.1 ACE APOE CRP EDN1 INS MTHFR
3 immune system MP:0005387 9.9 ACE APOE CRP INS NOS3 SELE
4 liver/biliary system MP:0005370 9.61 ACE APOE INS MTHFR NOS3 SELE
5 renal/urinary system MP:0005367 9.23 ACE APOE EDN1 INS NOS3 SELP

Drugs & Therapeutics for Vascular Disease

Drugs for Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 846)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ticlopidine Approved Phase 4 55142-85-3 5472
2
Ustekinumab Approved, Investigational Phase 4 815610-63-0
3
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
4
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
5
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
6
Famotidine Approved Phase 4 76824-35-6 3325
7
Dinoprostone Approved Phase 4 363-24-6 5280360
8
Methyltestosterone Approved Phase 4 58-18-4 6010
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
10
Testosterone enanthate Approved Phase 4 315-37-7 9416
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12
Nicotine Approved Phase 4 54-11-5 942 89594
13
Piperacillin Approved Phase 4 66258-76-2 43672
14
Remifentanil Approved Phase 4 132875-61-7 60815
15
Gliclazide Approved Phase 4 21187-98-4 3475
16
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
17
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
18
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
19
Iodine Approved, Investigational Phase 4 7553-56-2 807
20
Atenolol Approved Phase 4 29122-68-7 2249
21
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
22
Amlodipine Approved Phase 4 88150-42-9 2162
23
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
24
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
25
Travoprost Approved Phase 4 157283-68-6 5282226
26
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
27
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
28
Ofloxacin Approved Phase 4 82419-36-1 4583
29
Dobutamine Approved Phase 4 34368-04-2 36811
30
Donepezil Approved Phase 4 120014-06-4 3152
31
Sevelamer Approved Phase 4 52757-95-6
32
Calcium acetate Approved, Investigational Phase 4 62-54-4
33
Capsaicin Approved Phase 4 404-86-4 1548943
34
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
35
Enoxaparin Approved Phase 4 9005-49-6 772
36
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
37
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
38
Allopurinol Approved Phase 4 315-30-0 2094
39
Enalaprilat Approved Phase 4 76420-72-9 6917719
40
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
41
Povidone Approved Phase 4 9003-39-8
42
Metronidazole Approved Phase 4 443-48-1 4173
43
Ibuprofen Approved Phase 4 15687-27-1 3672
44
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
45
Rimonabant Approved, Investigational Phase 4 168273-06-1, 158681-13-1 104850
46
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
47
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
48
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
49
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
50
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877

Interventional clinical trials:

(show top 50) (show all 3584)
# Name Status NCT ID Phase Drugs
1 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
2 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
3 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
4 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
5 The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT03159884 Phase 4 Conbercept
6 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Unknown status NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
7 Eplerenone in the Management of Abdominal Aortic Aneurysms: A Proof-Of-Concept Randomised Controlled Trial Unknown status NCT02345590 Phase 4 Eplerenone
8 The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
9 Comparative Study of Covered Stent With Coil Embolization in the Treatment of Cranial Internal Carotid Artery Aneurysm: A Nonrandomized Prospective Trial Unknown status NCT01029938 Phase 4
10 Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
11 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
12 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
13 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo
14 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
15 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
16 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
17 Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Unknown status NCT00640731 Phase 4
18 Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in the Abdominal Position Unknown status NCT00824109 Phase 4
19 Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair. A Prospective, Randomised, Controlled Study Unknown status NCT01353443 Phase 4
20 Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
21 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
22 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
23 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
24 Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function Unknown status NCT02584075 Phase 4 Byetta (Exenatide);Glucophage ( Metformin Hydrochloride)
25 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
26 The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions Unknown status NCT01147419 Phase 4
27 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
28 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
29 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
30 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
31 A Prospective Randomized Multicenter Study of the Efficacy and Safety of Systematic Post -Dilatation With Noncompliant Balloon After Successful Drug-eluting Stent Implantation. IVUS Analysis. Unknown status NCT01103765 Phase 4
32 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
33 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
34 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
35 A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair Unknown status NCT01889498 Phase 4 Acetazolamide
36 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
37 A Randomised Controlled Trial of the Effectiveness of Ultrasound Guidance in Cannulation of Dialysis Arteriovenous Fistulas and Grafts in a University Hospital Dialysis Unit Unknown status NCT01163981 Phase 4
38 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
39 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
40 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
41 A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement Unknown status NCT01069042 Phase 4 Enalapril
42 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
43 Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels Unknown status NCT01176279 Phase 4
44 An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen Unknown status NCT03117634 Phase 4 Treat and Extend with Aflibercept 2mg;Fixed Dosing with Aflibercept 2mg
45 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
46 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
47 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
48 Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney. Unknown status NCT01208714 Phase 4 Optimal medical therapy
49 A Randomised, Double Blind, Placebo-controlled Parallel Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus Completed NCT00355537 Phase 4 Testosterone;0.9% saline
50 The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study Completed NCT00911417 Phase 4

Search NIH Clinical Center for Vascular Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Baclofen

Cochrane evidence based reviews: aneurysm

Genetic Tests for Vascular Disease

Anatomical Context for Vascular Disease

MalaCards organs/tissues related to Vascular Disease:

40
Endothelial, Heart, Smooth Muscle, Kidney, Brain, Lung, Testes

Publications for Vascular Disease

Articles related to Vascular Disease:

(show top 50) (show all 40218)
# Title Authors PMID Year
1
MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. 61 46
19542014 2009
2
MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. 61 46
17478730 2007
3
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 54 61
20232317 2010
4
Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. 54 61
20368328 2010
5
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. 54 61
20421882 2010
6
EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. 54 61
20203069 2010
7
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. 54 61
20518725 2010
8
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. 54 61
20466987 2010
9
Microvascular complications are associated with low levels of maternal sE-selectin and sVCAM-1 in pregnancy complicated with pregestational diabetes mellitus. 54 61
20129688 2010
10
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. 54 61
20079523 2010
11
Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. 54 61
20164116 2010
12
Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. 54 61
20110448 2010
13
Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: evidence for a hyperplastic vasculomyopathy. 54 61
20130469 2010
14
Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease. 54 61
20422735 2010
15
Weighting the potential of using tenascin C in diagnosis and therapy of atherosclerosis. 54 61
20513936 2010
16
High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1. 54 61
20079751 2010
17
APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. 54 61
19878946 2010
18
Upregulation of heme oxygenase-1 inhibits the maturation and mineralization of osteoblasts. 54 61
20020468 2010
19
Visfatin, glucose metabolism and vascular disease: a review of evidence. 54 61
20346149 2010
20
JNK-ATF-2 inhibits thrombomodulin (TM) expression by recruiting histone deacetylase4 (HDAC4) and forming a transcriptional repression complex in the TM promoter. 54 61
20116378 2010
21
An overview of the Guangzhou biobank cohort study-cardiovascular disease subcohort (GBCS-CVD): a platform for multidisciplinary collaboration. 54 61
19587700 2010
22
The association between the -374T/A polymorphism of the receptor for advanced glycation endproducts gene and blood pressure and arterial stiffness is modified by glucose metabolism status: the Hoorn and CoDAM studies. 54 61
20051912 2010
23
Endothelial nitric oxide synthase and nicotinamide adenosine dinucleotide phosphate oxidase p22phox gene (C242T) polymorphisms and systemic lupus erythematosus in a Chinese Population. 54 61
19965945 2010
24
Haptoglobin phenotype correlates with the extent of cerebral deep white matter lesions in hypertensive patients. 54 61
20158468 2010
25
The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. 54 61
20034371 2010
26
Paraoxonase 1 status as a risk factor for disease or exposure. 54 61
20221868 2010
27
Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients. 54 61
20185929 2010
28
C-reactive protein gene variant and the human left ventricular growth response to exercise: data from The LARGE Heart Study. 54 61
19834334 2010
29
The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. 54 61
20056946 2010
30
Plasma homocysteine, apolipoprotein E status and vascular disease in elderly patients with mental illness. 54 61
19943806 2010
31
Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. 54 61
20204740 2010
32
The protective role of adiponectin in pulmonary vascular disease. 54 61
19880503 2010
33
Telmisartan in high-risk cardiovascular patients. 54 61
20102972 2010
34
Homocysteine promotes vascular smooth muscle cell migration by induction of the adipokine resistin. 54 61
19828833 2009
35
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. 54 61
19916212 2009
36
Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. 54 61
19846878 2009
37
Coordinated regulation of angiopoietin-1 and vascular endothelial growth factor by arsenite in human brain microvascular pericytes: implications of arsenite-induced vascular dysfunction. 54 61
19622383 2009
38
Distribution of endothelial nitric oxide synthase gene polymorphisms in Turkish population. 54 61
19730129 2009
39
Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. 54 61
19360379 2009
40
Investigation of SERPINE1 genetic polymorphism in Macedonian patients with occlusive artery disease and deep vein thrombosis. 54 61
20017074 2009
41
Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. 54 61
19423112 2009
42
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. 54 61
19920927 2009
43
Tissue factor gene polymorphisms and haplotypes and the risk of ischemic vascular events: four studies and a meta-analysis. 54 61
19583819 2009
44
Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. 54 61
19576647 2009
45
Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. 54 61
19652200 2009
46
Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. 54 61
19778663 2009
47
Aspirin reduces the prothrombotic activity of C-reactive protein. 54 61
19522741 2009
48
A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. 54 61
19154538 2009
49
Haemostatic markers are associated with measures of vascular disease in adults with hypertension. 54 61
19190656 2009
50
The affinity of human RANK binding to its ligand RANKL. 54 61
19416721 2009